FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2752451504> ?p ?o ?g. }

• W2752451504 endingPage "408" @default.
• W2752451504 startingPage "395" @default.
• W2752451504 abstract "•Rifampin combinations have potential benefits in some patients with acute bacterial meningitis, infective endocarditis, pneumonia, and biofilm-related infections caused by non-mycobacterial organisms. •Rifampin combined with a cell-wall active agent is recommended for the treatment of staphylococcal prosthetic valve endocarditis. •There were no significant differences in outcome between patients who received colistin-rifampin and colistin alone for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia. Objectives Rifampin was initially approved for the treatment of tuberculosis. Because of its low toxicity, broad-spectrum activity, and good bioavailability, rifampin is now commonly administered as combination antimicrobial therapy for the treatment of various infections caused by organisms other than mycobacteria. This review summarizes the most recent clinical studies on the use of rifampin combinations for treating four common non-mycobacterial infections: acute bacterial meningitis, infective endocarditis and bacteraemia, pneumonia, and biofilm-related infections. Methods We performed a literature search of clinical studies published in English from January 2005 to June 2016 using the PubMed database with the search terms “rifampin” with “meningitis” or “infective endocarditis and bacteraemia” or “pneumonia” or “prosthetic joint infections. Results Current evidence to support a rifampin combination therapy as a treatment for non-mycobacterial infections was largely based on in vitro/in vivo studies and non-comparable retrospective case series. Additionally, controlled clinical trials that directly compared outcomes resulting from rifampin treatment versus treatment without rifampin were limited. Conclusions Rifampin combination therapy appears promising for the treatment of non-mycobacterial infections. However, further definitive clinical trials are necessary to validate its use because the risk of adverse drug–drug interactions and of the emergence of rifampin resistance during treatment may outweigh the potential benefits. Rifampin was initially approved for the treatment of tuberculosis. Because of its low toxicity, broad-spectrum activity, and good bioavailability, rifampin is now commonly administered as combination antimicrobial therapy for the treatment of various infections caused by organisms other than mycobacteria. This review summarizes the most recent clinical studies on the use of rifampin combinations for treating four common non-mycobacterial infections: acute bacterial meningitis, infective endocarditis and bacteraemia, pneumonia, and biofilm-related infections. We performed a literature search of clinical studies published in English from January 2005 to June 2016 using the PubMed database with the search terms “rifampin” with “meningitis” or “infective endocarditis and bacteraemia” or “pneumonia” or “prosthetic joint infections. Current evidence to support a rifampin combination therapy as a treatment for non-mycobacterial infections was largely based on in vitro/in vivo studies and non-comparable retrospective case series. Additionally, controlled clinical trials that directly compared outcomes resulting from rifampin treatment versus treatment without rifampin were limited. Rifampin combination therapy appears promising for the treatment of non-mycobacterial infections. However, further definitive clinical trials are necessary to validate its use because the risk of adverse drug–drug interactions and of the emergence of rifampin resistance during treatment may outweigh the potential benefits." @default.
• W2752451504 created "2017-09-15" @default.
• W2752451504 creator A5016879592 @default.
• W2752451504 creator A5019686478 @default.
• W2752451504 creator A5029043396 @default.
• W2752451504 creator A5033780365 @default.
• W2752451504 creator A5044201260 @default.
• W2752451504 creator A5077576855 @default.
• W2752451504 date "2017-11-01" @default.
• W2752451504 modified "2023-10-14" @default.
• W2752451504 title "Role of rifampin for the treatment of bacterial infections other than mycobacteriosis" @default.
• W2752451504 cites W1575086276 @default.
• W2752451504 cites W1764579138 @default.
• W2752451504 cites W1817751957 @default.
• W2752451504 cites W1831894185 @default.
• W2752451504 cites W1878404532 @default.
• W2752451504 cites W1905008412 @default.
• W2752451504 cites W1920355337 @default.
• W2752451504 cites W1928255277 @default.
• W2752451504 cites W1957527125 @default.
• W2752451504 cites W1970698283 @default.
• W2752451504 cites W1974052418 @default.
• W2752451504 cites W1975150477 @default.
• W2752451504 cites W1980520201 @default.
• W2752451504 cites W1986021215 @default.
• W2752451504 cites W1989180435 @default.
• W2752451504 cites W1992633342 @default.
• W2752451504 cites W1996810131 @default.
• W2752451504 cites W1996847287 @default.
• W2752451504 cites W1997275641 @default.
• W2752451504 cites W2003486401 @default.
• W2752451504 cites W2007527472 @default.
• W2752451504 cites W2009123817 @default.
• W2752451504 cites W2016632197 @default.
• W2752451504 cites W2018166454 @default.
• W2752451504 cites W2023057700 @default.
• W2752451504 cites W2024677412 @default.
• W2752451504 cites W2030667704 @default.
• W2752451504 cites W2030967154 @default.
• W2752451504 cites W2033135215 @default.
• W2752451504 cites W2034606737 @default.
• W2752451504 cites W2040119943 @default.
• W2752451504 cites W2055460437 @default.
• W2752451504 cites W2056654452 @default.
• W2752451504 cites W2058835846 @default.
• W2752451504 cites W2061187478 @default.
• W2752451504 cites W2061783494 @default.
• W2752451504 cites W2068372433 @default.
• W2752451504 cites W2075621134 @default.
• W2752451504 cites W2078576904 @default.
• W2752451504 cites W2079575346 @default.
• W2752451504 cites W2094740787 @default.
• W2752451504 cites W2096257534 @default.
• W2752451504 cites W2098025217 @default.
• W2752451504 cites W2098379446 @default.
• W2752451504 cites W2099018662 @default.
• W2752451504 cites W2099987405 @default.
• W2752451504 cites W2100556160 @default.
• W2752451504 cites W2101577939 @default.
• W2752451504 cites W2108152814 @default.
• W2752451504 cites W2108433768 @default.
• W2752451504 cites W2112660486 @default.
• W2752451504 cites W2113349916 @default.
• W2752451504 cites W2114014378 @default.
• W2752451504 cites W2117364775 @default.
• W2752451504 cites W2122767456 @default.
• W2752451504 cites W2123353572 @default.
• W2752451504 cites W2123870533 @default.
• W2752451504 cites W2124010765 @default.
• W2752451504 cites W2124742679 @default.
• W2752451504 cites W2130961698 @default.
• W2752451504 cites W2132620230 @default.
• W2752451504 cites W2132846513 @default.
• W2752451504 cites W2134377638 @default.
• W2752451504 cites W2136149867 @default.
• W2752451504 cites W2140603169 @default.
• W2752451504 cites W2142343447 @default.
• W2752451504 cites W2143206150 @default.
• W2752451504 cites W2145616988 @default.
• W2752451504 cites W2145644641 @default.
• W2752451504 cites W2146176840 @default.
• W2752451504 cites W2148594982 @default.
• W2752451504 cites W2149884385 @default.
• W2752451504 cites W2151069359 @default.
• W2752451504 cites W2153862563 @default.
• W2752451504 cites W2158143883 @default.
• W2752451504 cites W2162465551 @default.
• W2752451504 cites W2162560536 @default.
• W2752451504 cites W2163581302 @default.
• W2752451504 cites W2164292002 @default.
• W2752451504 cites W2164464065 @default.
• W2752451504 cites W2165249369 @default.
• W2752451504 cites W2166356134 @default.
• W2752451504 cites W2169388619 @default.
• W2752451504 cites W2212444540 @default.
• W2752451504 cites W2271867110 @default.
• W2752451504 cites W2272884487 @default.
• W2752451504 cites W2277716738 @default.

• next